Legrand Matthieu, Kothari Rishi, Fong Nicholas, Palaniappa Nandini, Boldt David, Chen Lee-Lynn, Kurien Philip, Gabel Eilon, Sturgess-DaPrato Jillene, Harhay Michael O, Pirracchio Romain, Bokoch Michael P
Department of Anesthesia and Perioperative Care, University of California, San Francisco, CA, USA; INI-CRCT Network, Nancy, France.
Department of Anesthesia and Perioperative Care, University of California, San Francisco, CA, USA; Department of Anesthesiology and Perioperative Medicine, Thomas Jefferson University, Philadelphia, PA, USA.
Br J Anaesth. 2023 May;130(5):519-527. doi: 10.1016/j.bja.2023.02.004. Epub 2023 Mar 14.
Intraoperative hypotension is associated with postoperative complications. The use of vasopressors is often required to correct hypotension but the best vasopressor is unknown.
A multicentre, cluster-randomised, crossover, feasibility and pilot trial was conducted across five hospitals in California. Phenylephrine (PE) vs norepinephrine (NE) infusion as the first-line vasopressor in patients under general anaesthesia alternated monthly at each hospital for 6 months. The primary endpoint was first-line vasopressor administration compliance of 80% or higher. Secondary endpoints were acute kidney injury (AKI), 30-day mortality, myocardial injury after noncardiac surgery (MINS), hospital length of stay, and rehospitalisation within 30 days.
A total of 3626 patients were enrolled over 6 months; 1809 patients were randomised in the NE group, 1817 in the PE group. Overall, 88.2% received the assigned first-line vasopressor. No drug infiltrations requiring treatment were reported in either group. Patients were median 63 yr old, 50% female, and 58% white. Randomisation in the NE group vs PE group did not reduce readmission within 30 days (adjusted odds ratio=0.92; 95% confidence interval, 0.6-1.39), 30-day mortality (1.01; 0.48-2.09), AKI (1.1; 0.92-1.31), or MINS (1.63; 0.84-3.16).
A large and diverse population undergoing major surgery under general anaesthesia was successfully enrolled and randomised to receive NE or PE infusion. This pilot and feasibility trial was not powered for adverse postoperative outcomes and a follow-up multicentre effectiveness trial is planned.
NCT04789330 (ClinicalTrials.gov).
术中低血压与术后并发症相关。纠正低血压通常需要使用血管升压药,但最佳的血管升压药尚不清楚。
在加利福尼亚州的五家医院进行了一项多中心、整群随机、交叉、可行性和试点试验。苯肾上腺素(PE)与去甲肾上腺素(NE)输注作为全身麻醉患者的一线血管升压药,每家医院每月交替使用6个月。主要终点是一线血管升压药给药依从性达到80%或更高。次要终点包括急性肾损伤(AKI)、30天死亡率、非心脏手术后心肌损伤(MINS)、住院时间和30天内再入院。
6个月内共纳入3626例患者;NE组随机分配1809例患者,PE组随机分配1817例患者。总体而言,88.2%的患者接受了指定的一线血管升压药。两组均未报告需要治疗的药物渗漏情况。患者的中位年龄为63岁,50%为女性,58%为白人。NE组与PE组随机分组并未降低30天内再入院率(调整后的优势比=0.92;95%置信区间,0.6-1.39)、30天死亡率(1.01;0.48-2.09)、AKI(1.1;0.92-1.31)或MINS(1.63;0.84-3.16)。
成功纳入了大量接受全身麻醉下大手术的不同人群,并随机接受NE或PE输注。这项试点和可行性试验没有足够的能力检测术后不良结局,计划进行后续的多中心有效性试验。
NCT04789330(ClinicalTrials.gov)。